Email:
Why ICO?
ICO's greatest strengths are its comprehensive curriculum and complex patient population, both of which create strong student clinicians. At IEI we consider the entire patient including refractive error, binocular vision, ocular health, and systemic disease.
Biography
After earning a bachelor's degree at the University of Central Florida, Dr. Adams obtained her OD/PhD dual degree through New England College of Optometry and Boston University, conducting research on the protein expression of novel genetic associations with late-onset Alzheimer’s disease. With an interest in ocular pathology, Dr. Adams then completed a residency at the West Roxbury Boston VA Hospital. At ICO she served as an assistant professor and clinical faculty member from 2019-2022. Presently Dr. Adams continues to collaborate in clinical research at ICO and conducts remote clinical enhancement sessions with students.
Special Interests
Ocular and neurological disease, educational research, technology-based innovations in teaching
Education
University of Central Florida B.S
New England College of Optometry OD
Boston University PhD
West Roxbury VA Boston Healthcare System, Ocular Disease Residency
Experience
2022-present Vancouver Vision Clinic, Vancouver, WA
2019-present Illinois College of Optometry, Chicago, IL
2018-2019 West Roxbury VA Hospital, Boston, MA
Awards & Honors
The National Association of VA Optometrists (NAVAO) Resident Scholarship, 2018
National Board of Examiners in Optometry Certificate of Commendation, 2014
Professional Organizations
Fellow of the American Academy of Optometry
Optometric Physicians of Washington
Illinois Optometric Association
Association of Schools and Colleges of Optometry
Publications
Optometric Education 2020; 46(1). A Novel Approach to Clinical Education through Distance Learning. Stephanie L. Adams OD PhD & Elizabeth Wyles OD FAAO.
Journal of Alzheimer’s Disease 2019;68(1):357-365. doi: 10.3233/JAD-180977. Methionine Sulfoxide Reductase-B3 risk allele implicated in Alzheimer’s disease increases odds for brain infarcts. Sarah C. Conner, Laurent Benayoun, Jayandra Himali PhD, Stephanie L. Adams PhD, Qiong Yang, Charles DeCarli MD, Jan Blusztajn, PhD, Alexa Beiser PhD, Sudha Seshadri, MD, and Ivana Delalle, MD, PhD
Journal of Alzheimer’s Disease 2019;68(1):357-365. doi: 10.3233/JAD-180977. Methionine Sulfoxide Reductase-B3 risk allele implicated in Alzheimer’s disease increases odds for brain infarcts. Sarah C. Conner, Laurent Benayoun, Jayandra Himali PhD, Stephanie L. Adams PhD, Qiong Yang, Charles DeCarli MD, Jan Blusztajn, PhD, Alexa Beiser PhD, Sudha Seshadri, MD, and Ivana Delalle, MD, PhD
Journal of Alzheimer’s Disease 2018; 63 (4): 1433-43. doi: 10.3233/JAD-171065. Immunohistochemical Analysis of Activin Receptor-Like Kinase 1 (ACVRL1/ALK1) Expression in the Rat and Human Hippocampus: Decline in CA3 During Progression of Alzheimer’s Disease. Stephanie L. Adams, Laurent Benayoun, Kathy Tilton, Tiffany Mellott, PhD, Sudha Seshadri, MD, Jan Krzysztof Blusztajn, PhD, and Ivana Delalle, MD, PhD
Journal of Alzheimer’s Disease 2017; 60 (1): 43-56. doi: 10.3233/JAD-170459. Methionine sulfoxide reductase-B3 (MsrB3) protein associates with synaptic vesicles and its expression changes in the hippocampi of Alzheimer’s disease patients. Stephanie L. Adams, Laurent Benayoun, Kathy Tilton, Olivia R. Chavez, MS, Jayandra J. Himali, PhD, Jan Krzysztof Blusztajn, PhD, Sudha Seshadri, MD, and Ivana Delalle, MD, PhD
Journal of Neuropathology & Experimental Neurology 2016, 75 (8) 779-790. Subcellular Changes in Bridging Integrator 1 Protein Expression in the Cerebral Cortex During the Progression of Alzheimer Disease Pathology. Stephanie L. Adams, Kathy Tilton, James Kozubek MS, Sudha Seshadri MD, Ivana Delalle, MD PhD.
